Alumis
Philip Nunn has extensive work experience in the pharmaceutical industry. Philip currently serves as the Senior Vice President of Preclinical Development at Alumis, a position they have held since September 2021. Prior to their role at Alumis, they worked at Principia Biopharma for several years, where they held various senior positions, including Senior Vice President of Early Development and Pharmacology, Vice President of Early Development and Pharmacology AI Head of Biology, and Senior Director Head of Pharmacology. At Principia Biopharma, they were responsible for managing toxicology, DMPK, bio-analytics, and translational biology for research and development programs. Philip also served as the project leader for a Phase 2 BTK inhibitor. Before joining Principia Biopharma, Philip worked at Roche as a Senior Global Project Manager and Associate Director, overseeing drug development projects targeting oncology and viral diseases. Philip played a crucial role in project management, communication, strategy development, and implementation. Philip began their career at Pfizer GRD as a Senior Scientist.
Philip Nunn attended multiple educational institutions throughout their life. In 1979, they completed their secondary education at Wreake Valley Community College. From 1985 to 1988, they pursued Applied Biology (Pharmacology/Toxicology) at De Montfort University. Subsequently, they studied Pharmacology/Physiology at The University of Sheffield from 1988 to 1991. In 2010, they obtained a Mini-MBA in Biopharmaceutical Innovation from Rutgers University - Newark. Finally, in 2011, they attended the Project Management Institute to earn their Project Management Professional Certification (PMP).
Alumis
2 followers
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.